1. | karinkaz | |
2. | rjsllewellyn | |
3. | fpratt |
1. | karinkaz | |
2. | rjsllewellyn | |
3. | fpratt |
1. | fpratt 06/01/2018 Orphan Drug Designation from the European Commission for bardoxolone methyl |
2. | karinkaz 03/01/2018 Reports top-line data from dose-escalation cohorts in motor study of omaveloxolone in patients with mitochon… |
3. | karinkaz 04/25/2018 Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich's Ataxia and Other Severe Neurological Diseases |
4. | rjsllewellyn 02/28/2018 Reata Provides Program Update on Phase 2 Rare Renal Clinical Trials |
5. | rjsllewellyn 02/13/2018 Reata Announces Improvements in Kidney Function With Bardoxolone Methyl Maintained for Two Years in PAH Patients From LARIAT Trial |
6. | karinkaz 03/30/2018 Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan |
7. | karinkaz 02/12/2018 long-term follow up |
8. | karinkaz 04/24/2018 Announces new preclinical data |
9. | rjsllewellyn 03/22/2018 Announces positive top-line data from the Phase 2 LARIAT trial evaluating bardoxolone methyl for the treatme… |
10. | rjsllewellyn 07/10/2018 Reata Receives Orphan Drug Designation from the European Commission for Omaveloxolone for the Treatment of Friedreich's Ataxia |